Suppr超能文献

[轻度克罗恩病和轻度溃疡性结肠炎的有效治疗]

[Efficient treatment of mild Crohn's disease and mild ulcerative colitis].

作者信息

Rogler Gerhard

机构信息

Klinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz.

出版信息

Inn Med (Heidelb). 2025 Jan;66(1):15-21. doi: 10.1007/s00108-024-01840-x. Epub 2024 Dec 23.

Abstract

The cornerstone of treatment for mild ulcerative colitis is still the oral or topical (rectal) application of aminosalicylates (5-ASA). 5‑ASA preparations are often only administered orally in mild ulcerative colitis. Study data show that in ulcerative proctitis and left-sided colitis, rectal 5‑ASA preparations are even more effective than oral administration. In a next step, steroid-containing topical therapies should be used. Topical steroids such as budesonide are also primarily used in mild Crohn's disease. However, it is controversial whether treatment is necessary in symptom-free patients. There is still a lack of evidence to prove that more aggressive treatment (using immunosuppressants, biologics or small molecules) has a long-term benefit in these patients. Most guidelines are critical of the use of 5‑ASA in mild Crohn's disease. Nevertheless, there is some evidence for sufficiently high-dose treatment with 5‑ASA, although one must be aware of its limited effectiveness. However, there is clear evidence for the postoperative use of 5‑ASA in cases of mild recurrence.

摘要

轻度溃疡性结肠炎的治疗基石仍然是口服或局部(直肠)应用氨基水杨酸酯(5-ASA)。在轻度溃疡性结肠炎中,5-ASA制剂通常仅口服给药。研究数据表明,在溃疡性直肠炎和左侧结肠炎中,直肠用5-ASA制剂比口服给药更有效。下一步应使用含类固醇的局部治疗。布地奈德等局部类固醇也主要用于轻度克罗恩病。然而,无症状患者是否需要治疗存在争议。仍然缺乏证据证明更积极的治疗(使用免疫抑制剂、生物制剂或小分子药物)对这些患者有长期益处。大多数指南对在轻度克罗恩病中使用5-ASA持批评态度。尽管如此,有一些证据支持用足够高剂量的5-ASA进行治疗,不过必须意识到其有效性有限。然而,有明确证据表明在轻度复发的情况下术后使用5-ASA。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e1/11761793/caa0886a5af9/108_2024_1840_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验